Corporate Updates

Aurobindo Pharma acquires 7 oncology products from US company for $300 mn

Aurobindo Pharma has announced that it has completed the acquisition of seven marketed oncology injectable products, intellectual property and commercial infrastructure from Spectrum Pharmaceuticals Inc, a US-based global branded oncology company by Acrotech Biopharma.


In January, Aurobindo Pharma had said it will acquire a portfolio of seven branded oncology injectable products from Spectrum Pharmaceuticals Inc in a $300 million deal (over Rs 2,100 crore) which includes an upfront cash payment of $160 million.

“We would like to inform you that the acquisition has been completed on March 1,” Aurobindo Pharma said in a regulatory filing to the BSE recently.

According to the definitive agreements inked between the two companies, Acrotech Biopharma LLC, a subsidiary of Aurobindo, will pay an upfront purchase price of $160 million in cash plus up to $ 140 million on achieving regulatory and sales-based milestones for the seven products.


Acrotech will be acquiring the product portfolio on a debt free and cash free basis, Aurobindo Pharma Ltd said.

The acquisition will help Hyderabad-based company to enter the branded oncology market in the US with a range of products which are well recognised in the segment, it added.

Follow and connect with us on Facebook, Twitter, LinkedIn, Elets video

Eletsonline News

Follow us on

Most Popular

200000+ Subscribers read it every day.
Subscribe Newsletter
To Top